GlassScriptPhysician profile
Casey L Morris
NPI 1518621739
$4,967.14
in general payments reported to CMS, 2019-2025
29 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,335 · 2023: $2,836 · 2024: $290 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,631.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,693.65 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $536.22 | 2022-2023 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $306.16 | 2022-2023 | Ocaliva |
| Pfizer INC. | $284.09 | 2022-2024 | |
| Janssen Biotech, INC. | $219.08 | 2022-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $171.90 | 2022-2023 | Gattex, Entyvio |
| Regeneron Healthcare Solutions, INC. | $159.99 | 2023 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $154.87 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $138.56 | 2023 | Epclusa |
| Ironwood Pharmaceuticals, INC | $136.79 | 2022-2023 | Linzess |
| Janssen Scientific Affairs, LLC | $130.81 | 2022-2025 | Remicade, Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $122.66 | 2024 | Voquezna |
| Genzyme Corporation | $120.58 | 2022-2023 | |
| Medtronic, INC. | $115.78 | 2023 | Interstim |
| Sumitomo Pharma America, INC. | $92.60 | 2025 | Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $80.70 | 2022-2023 | |
| Celgene Corporation | $63.82 | 2022-2023 | Zeposia |
| Fresenius Kabi USA, LLC | $61.80 | 2023 | Idacio |
| Evoke Pharma, INC. | $56.84 | 2022-2023 | Gimoti |
| Aimmune Therapeutics, INC. | $53.09 | 2024 | |
| Ardelyx, INC. | $48.97 | 2023 | Ibsrela |
| Qol Medical, LLC | $46.63 | 2022 | |
| Madrigal Pharmaceuticals | $44.34 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $36.77 | 2023 | Dificid |
| Ferring Pharmaceuticals INC. | $23.77 | 2023 | Rebyota |
| Daiichi Sankyo INC. | $20.75 | 2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $18.82 | 2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.30 | 2023 | Cyltezo |
| Amgen INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.